A detailed history of Ameriprise Financial Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 15,231 shares of NRIX stock, worth $409,104. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,231
Previous 46,804 67.46%
Holding current value
$409,104
Previous $976,000 65.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$18.93 - $25.69 $597,676 - $811,110
-31,573 Reduced 67.46%
15,231 $341,000
Q2 2024

Aug 14, 2024

SELL
$12.02 - $21.3 $709,901 - $1.26 Million
-59,060 Reduced 55.79%
46,804 $976,000
Q1 2024

May 15, 2024

SELL
$7.77 - $15.66 $37,668 - $75,919
-4,848 Reduced 4.38%
105,864 $1.56 Million
Q4 2023

Feb 14, 2024

BUY
$4.25 - $10.71 $214,174 - $539,719
50,394 Added 83.55%
110,712 $1.14 Million
Q3 2023

Nov 14, 2023

BUY
$7.86 - $10.08 $474,099 - $608,005
60,318 New
60,318 $474,000
Q1 2023

May 15, 2023

BUY
$8.56 - $13.26 $153,643 - $238,003
17,949 Added 79.07%
40,649 $360,000
Q4 2022

Feb 14, 2023

BUY
$9.86 - $14.59 $223,822 - $331,193
22,700 New
22,700 $249,000
Q3 2021

Nov 15, 2021

SELL
$22.71 - $36.69 $5.1 Million - $8.24 Million
-224,686 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$24.21 - $35.89 $122,623 - $181,782
5,065 Added 2.31%
224,686 $5.96 Million
Q1 2021

May 17, 2021

BUY
$26.98 - $50.17 $2.45 Million - $4.56 Million
90,821 Added 70.51%
219,621 $6.83 Million
Q4 2020

Feb 12, 2021

SELL
$22.85 - $48.44 $2.89 Million - $6.13 Million
-126,448 Reduced 49.54%
128,800 $4.24 Million
Q3 2020

Nov 16, 2020

BUY
$16.05 - $34.91 $4.1 Million - $8.91 Million
255,248 New
255,248 $8.91 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1.27B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.